18 related articles for article (PubMed ID: 38583239)
1. [Clinicopathological characteristics of the CD8
Chai X; Sun Z; Li H; Zhu L; Liu X; Liu Y; Pei F; Chang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):512-518. PubMed ID: 38864138
[TBL] [Abstract][Full Text] [Related]
2. Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer.
Bakkerus L; Subtil B; Bontkes HJ; Gootjes EC; Reijm M; Vullings M; Verrijp K; Bokhorst JM; Woortman C; Nagtegaal ID; Jonker MA; van der Vliet HJ; Verhoef C; Gorris MAJ; de Vries IJM; de Gruijl TD; Verheul HMW; Buffart TE; Tauriello DVF
Oncoimmunology; 2024; 13(1):2361971. PubMed ID: 38868078
[TBL] [Abstract][Full Text] [Related]
3. Th17 cells inhibit CD8
Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
[TBL] [Abstract][Full Text] [Related]
4. Th9 cells are subjected to PD-1/PD-L1-mediated inhibition and are capable of promoting CD8 T cell expansion through IL-9R in colorectal cancer.
Wang C; Lu Y; Chen L; Gao T; Yang Q; Zhu C; Chen Y
Int Immunopharmacol; 2020 Jan; 78():106019. PubMed ID: 31776089
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
6. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
7. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
[TBL] [Abstract][Full Text] [Related]
8. Expressions of CXCR3 and PD-1 on T cells and their clinical relevance in colorectal cancer.
Wang S; Zhang Y; Chen G; Zhao P; Wang X; Xu B; Yuan L
Int Immunopharmacol; 2024 May; 132():111988. PubMed ID: 38583239
[TBL] [Abstract][Full Text] [Related]
9. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]